[Deciphering cellular processes responding to lethality of 17 β-estradiol by quantitative phosphoproteomics]

Se Pu. 2024 Apr;42(4):333-344. doi: 10.3724/SP.J.1123.2023.04025.
[Article in Chinese]

Abstract

17β-Estradiol (E2), an important endocrine hormone in the mammalian body, participates in the regulation of the physiological functions of the reproductive system, mammary glands, bone, and cardiovascular system, among others. Paradoxically, despite the physiological actions of endogenous E2 (0.2-1.0 nmol/L), numerous clinical and experimental studies have demonstrated that high-dose E2 treatment can cause tumor regression and exert pro-apoptotic actions in multiple cell types; however, the underlying mechanism remains undescribed. In particular, little information of the cellular processes responding to the lethality of E2 is available. In the present study, we attempted to characterize the cellular processes responding to high-dose (μmol/L) E2 treatment using quantitative phosphoproteomics to obtain a better understanding of the regulatory mechanism of E2-induced cell death. First, the cell phenotype induced by high-dose E2 was determined by performing Cell Counting Kit-8 assay (CCK8), cell cytotoxicity analysis by trypan blue staining, and microscopic imaging on HeLa cells treated with 1-10 μmol/L E2 or dimethyl sulfoxide (DMSO) for 1-3 d. E2 inhibited cell proliferation and induced cell death in a dose- and time-dependent manner. Compared with the DMSO-treated HeLa cells, the cells treated with 5 μmol/L E2 for 2 d demonstrated >74% growth inhibition and approximately 50% cell death. Thus, these cells were used for quantitative phosphoproteomic analysis. Next, a solid-phase extraction (SPE)-based immobilized titanium ion affinity chromatography (Ti4+-IMAC) phosphopeptide-enrichment method coupled with data-independent acquisition (DIA)-based quantitative proteomics was employed for the in-depth screening of high-dose E2-regulated phosphorylation sites to investigate the intracellular processes responding to high-dose E2 treatment. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified over 10000 phosphorylation sites regulated by E2 and DMSO in HeLa cells. In comparison with the DMSO-treated cells, the cells treated with 5 μmol/L E2 showed 537 upregulated phosphorylation sites and 387 downregulated phosphorylation sites, with a threshold of p<0.01 and |log2(fold change)|≥1. A total of 924 phosphorylation sites on 599 proteins were significantly regulated by high-dose E2, and these sites were subjected to enrichment analysis. In addition, 453 differently regulated phosphorylation sites on 325 proteins were identified only in the E2- or DMSO-treated cell samples. These phosphorylation sites may be phosphorylated or dephosphorylated in response to high-dose E2 stimulation and were subjected to parallel enrichment analyses. Taken together, 1218 phosphorylation sites on 741 proteins were significantly regulated by high-dose E2 treatment. The functional phosphoproteins in these two groups were then analyzed using Gene Ontology (GO) and Gene Set Enrichment Analysis (GSEA) to determine the biological processes in which they participate and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database. Consistent with the cell-phenotype data, cell cycle-related proteins were highly enriched in the two groups of E2-regulated phosphoproteins (p<0.05), indicating that high-dose E2 treatment can regulate cell proliferation. In addition, E2-regulated phosphoproteins were highly enriched in the cellular processes of ribosome biogenesis, nucleocytoplasmic transport, and messenger ribonucleic acid (mRNA) processing/splicing (p<0.05), indicating that the activation of these processes may contribute to high-dose E2-induced cell death. These results further confirm that high-dose E2 treatment inhibits protein translation and induces cell death. Furthermore, the significant upregulation of multiple phosphorylation sites associated with epidermal growth factor receptor (EGFR) and mitogen-activated protein kinases (MAPKs) MAPK1, MAPK4, and MAPK14 by high-dose E2 indicates that the EGFR and MAPK signaling pathways are likely involved in the regulation of E2-induced cell death. These phosphorylation sites likely play vital roles in E2-induced cell death in HeLa cells. Overall, our phosphoproteomic data could be a valuable resource for uncovering the regulatory mechanisms of E2 in the micromolar range.

17β-雌二醇(E2)是人体内一种重要的内分泌激素,在生理浓度下(0.2~1.0 nmol/L)对生殖系统、乳腺等靶器官的生长发育起着重要的调节作用。但很多研究表明,高剂量(μmol/L~mmol/L)的E2能够诱导肿瘤组织消退和细胞凋亡,其具体调控机制尚不明确。本工作聚焦于高剂量(μmol/L)的E2致死效应,首先分析了μmol/L水平的E2对HeLa细胞表型的影响,发现在1~10 μmol/L下E2以浓度依赖的形式抑制HeLa细胞增殖,并诱导HeLa细胞发生死亡,其中,用5 μmol/L E2处理2天后可使约74%的HeLa细胞增殖受到抑制,并引起约50%的HeLa细胞死亡。在此基础上,为了探究高剂量E2诱导细胞死亡的内在调控过程,将基于固相萃取(SPE)的固定化钛离子亲和色谱技术(Ti4+-IMAC)与基于数据非依赖采集模式(DIA)的蛋白质组定量技术结合,用于筛选HeLa细胞内参与高剂量(μmol/L)E2致死效应调控过程的磷酸化位点。最终,在5 μmol/L E2和二甲基亚砜(DMSO)处理的HeLa细胞中共鉴定到超过10000个磷酸化位点; t检验分析发现, 在E2处理后, 有924个磷酸化位点(对应599个蛋白质)的丰度发生了显著变化(显著性水平(p)<0.01, |log2(倍数变化)|≥1), 推测其可能参与调控E2致死效应过程。此外,有453个磷酸化位点(对应325个蛋白质)仅单独发生在E2或DMSO处理后的HeLa细胞样品中,表明这些磷酸化位点在E2处理后发生了磷酸化或去磷酸化,也可能参与E2致死效应的调控过程。分别对以上两种方式筛选的E2调控的磷酸化蛋白质进行富集分析, 发现这些磷酸化蛋白质主要参与细胞分裂、核糖体/核质转运、信使核糖核酸(mRNA)加工/剪接及转录等过程,表明高剂量的E2可能通过调控核糖体及mRNA加工等过程影响蛋白质转录,进而诱导细胞发生死亡。此外,我们发现表皮生长因子受体(EGFR)和丝裂原活化蛋白激酶(MAPK)家族蛋白(包括MAPK1、MAPK4和MAPK14)上多个磷酸化位点的修饰水平在高剂量E2处理后发生了明显变化,表明EGFR和MAPK信号通路可能在雌激素诱导的细胞死亡中起着重要调控作用。本实验得到的磷酸化蛋白质组定量结果有助于进一步了解高剂量E2的内在调控过程,为后续解析高剂量E2的作用机制及疾病的治疗提供了参考。

Keywords: 17β-estradiol (E2); data-independent acquisition (DIA); estrogen; immobilized titanium ion affinity chromatography (Ti4+-IMAC); lethal effect; liquid chromatography-tandem mass spectrometry (LC-MS/MS); phosphoprotoemics.

Publication types

  • English Abstract

MeSH terms

  • Animals
  • Chromatography, Liquid
  • Dimethyl Sulfoxide*
  • ErbB Receptors / metabolism
  • Estradiol / pharmacology
  • HeLa Cells
  • Humans
  • Mammals / metabolism
  • Phosphoproteins / chemistry
  • Phosphoproteins / metabolism
  • Phosphorylation
  • Tandem Mass Spectrometry*

Substances

  • Dimethyl Sulfoxide
  • Estradiol
  • Phosphoproteins
  • ErbB Receptors